Search Results - "Ryu, M. H."

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) by Boku, N., Ryu, M.-H., Kato, K., Chung, H.C., Minashi, K., Lee, K.-W., Cho, H., Kang, W.K., Komatsu, Y., Tsuda, M., Yamaguchi, K., Hara, H., Fumita, S., Azuma, M., Chen, L.-T., Kang, Y.-K.

“…Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after…”
Get full text

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 by Bang, Y.-J, Ruiz, E.Yañez, Van Cutsem, E., Lee, K.-W, Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H, Chung, H.-C, Evesque, L., Al-Batran, S.-E, Park, S.H., Lichinitser, M., Boku, N., Moehler, M.H., Hong, J., Xiong, H., Hallwachs, R., Conti, I., Taieb, J.

“…There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC)…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS by Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Kato, K., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Nakajima, T.E., Shitara, K., Kawakami, H., Tsushima, T., Yoshino, T., Lordick, F., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS by Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Kato, K., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Nakajima, T.E., Shitara, K., Kawakami, H., Narita, Y., Yoshino, T., Van Cutsem, E., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of…”
Get full text

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study by Gazzah, A., Bedard, P.L., Hierro, C., Kang, Y.-K., Abdul Razak, A., Ryu, M.-H., Demers, B., Fagniez, N., Henry, C., Hospitel, M., Soria, J.-C., Tabernero, J.

“…Tusamitamab ravtansine (SAR408701) is an antibody–drug conjugate composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell…”
Get full text

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma by Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Caglevic, C., Chung, H.C., Muro, K., Van Cutsem, E., Kobie, J., Cristescu, R., Aurora-Garg, D., Lu, J., Shih, C.-S., Adelberg, D., Cao, Z.A., Fuchs, C.S.

“…In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for…”
Get full text

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy by Kang, Y.-K., Ryu, M.-H., Park, S.H., Kim, J.G., Kim, J.W., Cho, S.-H., Park, Y.-I., Park, S.R., Rha, S.Y., Kang, M.J., Cho, J.Y., Kang, S.Y., Roh, S.Y., Ryoo, B.-Y., Nam, B.-H., Jo, Y.-W., Yoon, K.-E., Oh, S.C.

“…Paclitaxel is currently only available as an intravenous (i.v.) formulation. DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107…”
Get full text

Effects of melatonin receptor expression on prognosis and survival in oral squamous cell carcinoma patients by Park, H.-K., Ryu, M.-H., Hwang, D.-S., Kim, G.-C., Jang, M.-A., Kim, U.-K.

“…Melatonin receptors can inhibit breast and prostate cancers; however, little is known regarding their effects on oral squamous cell carcinoma. In this study,…”
Get full text

Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors by Yoo, C., Ryu, M.-H., Na, Y.S., Ryoo, B.-Y., Park, S.R., Kang, Y.-K.

“…An exploratory translational analysis was conducted as part of a phase II study of dovitinib to assess the relevance of soluble serum proteins and circulating…”
Get full text

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis by Kim, H.S., Kim, H.J., Kim, S.Y., Kim, T.Y., Lee, K.W., Baek, S.K., Ryu, M.H., Nam, B.H., Zang, D.Y.

“…Many patients with refractory or relapsed gastric cancer after first-line chemotherapy have received salvage chemotherapy in routine clinical practice…”
Get full text

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS) by Ryu, M.-H., Baba, E., Lee, K.H., Park, Y.I., Boku, N., Hyodo, I., Nam, B.-H., Esaki, T., Yoo, C., Ryoo, B.-Y., Song, E.-K., Cho, S.-H., Kang, W.K., Yang, S.H., Zang, D.Y., Shin, D.B., Park, S.R., Shinozaki, K., Takano, T., Kang, Y.-K.

“…Five-weekly S-1 plus cisplatin (SP5) is one of the standard first-line regimens for advanced gastric cancer (GC), proven in a Japanese phase III study. To…”
Get full text

Impact of extranodal extension on prognosis in lymph node-positive gastric cancer by Lee, I.-S., Park, Y.-S., Ryu, M.-H., Song, M. J., Yook, J.-H., Oh, S.-T., Kim, B.-S.

“…Background The TNM classification system is used widely for tumour staging, and directs the treatment and prognosis of patients with cancer. The aim of this…”
Get full text

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum by Yoon, D H, Ryu, M-H, Park, Y S, Lee, H J, Lee, C, Ryoo, B-Y, Lee, J-L, Chang, H-M, Kim, T W, Kang, Y-K

“…Background: To evaluate the activity and safety of everolimus and identify potential biomarkers for efficacy of everolimus in patients with advanced gastric…”
Get full text

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib by Kang, Y-K, Yoo, C, Ryoo, B-Y, Lee, J J, Tan, E, Park, I, Park, J H, Choi, Y J, Jo, J, Ryu, J-S, Ryu, M-H

“…Background: This prospective, phase II trial evaluated the efficacy and safety of dovitinib in patients with metastatic and/or unresectable gastrointestinal…”
Get full text

Quantitative multiplexed immune profiling of advanced gastrointestinal stromal tumors (GISTs): Impact of tyrosine kinase inhibitors on immune environment by Yoo, C., Kim, S.-Y., Kim, J., Ryu, Y.-M., Ryu, M.-H., Kang, Y.-K.

Get full text

Systemic steroid treatment for severe skin rash induced by imatinib in patients with gastrointestinal stromal tumor (GIST): A phase II study by Kim, E., Ryu, M.-H., Park, S.R., Beck, M.Y., Lee, W.J., Lee, M.W., Kang, Y.-K.

Get full text

A phase III study of adjuvant docetaxel, capecitabine and oxaliplatin triplet vs capecitabine and oxaliplatin doublet in patients with curatively resected stage IIIB or IV(M0) (AJCC 6th ed) gastric adenocarcinoma (TRIUMPH, KCSG ST14-05) by Ryu, M.-H., Zang, D.Y., Lee, K.-W., Shim, B.Y., Lee, M.H., Rha, S.Y., Kang, Y.-K.

Get full text

Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics by Yan, D., Ryu, M.-H., An, E., Park, Y.S., Na, H., Ma, J., Tian, Y., Cecchi, F., Hembrough, T., Kang, Y.-K.

Get full text

Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib by Cho, H., Ryu, M.-H., Kim, B.J., Park, Y., Na, Y.-S., Ma, J., Beck, M.Y., Kang, Y.-K.

Get full text

Neutrophil-lymphocyte ratio (NLR) as an important prognostic factor for paclitaxel as a second line chemotherapy in advanced gastric cancer (AGC): Results from phase III DREAM study by Ryu, M.-H., Kim, J.H., Oh, S.C., Park, S., Kim, J.G., Kim, J.W., Cho, S.-H., Yoon, K.-E., Kang, Y.-K.

Get full text